

Nicolas Clementy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5943983/publications.pdf>

Version: 2024-02-01

57
papers

1,791
citations

331538

21
h-index

276775

41
g-index

58
all docs

58
docs citations

58
times ranked

2349
citing authors

#	ARTICLE	IF	CITATIONS
1	A leadless pacemaker in the real-world setting: The Micra Transcatheter Pacing System Post-Approval Registry. <i>Heart Rhythm</i> , 2017, 14, 1375-1379.	0.3	251
2	Updated performance of the Micra transcatheter pacemaker in the real-world setting: A comparison to the investigational study and a transvenous historical control. <i>Heart Rhythm</i> , 2018, 15, 1800-1807.	0.3	239
3	Effects of remote monitoring on clinical outcomes and use of healthcare resources in heart failure patients with biventricular defibrillators: results of the MORECARE multicentre randomized controlled trial. <i>European Journal of Heart Failure</i> , 2017, 19, 416-425.	2.9	165
4	Stroke and Major Bleeding Risk in Elderly Patients Aged ≥75 Years With Atrial Fibrillation. <i>Stroke</i> , 2015, 46, 143-150.	1.0	116
5	Accelerometer-based atrioventricular synchronous pacing with a ventricular leadless pacemaker: Results from the Micra atrioventricular feasibility studies. <i>Heart Rhythm</i> , 2018, 15, 1363-1371.	0.3	116
6	Patients With Ischemic Stroke and Incident Atrial Fibrillation. <i>Stroke</i> , 2015, 46, 2432-2437.	1.0	77
7	Incidence and predictors of sudden death, major conduction defects and sustained ventricular tachyarrhythmias in 1388 patients with myotonic dystrophy type 1. <i>European Heart Journal</i> , 2017, 38, ehw569.	1.0	59
8	Should Atrial Fibrillation Patients With Only 1 Nongender-Related CHA ₂ DS ₂ -VASc Risk Factor Be Anticoagulated?. <i>Stroke</i> , 2016, 47, 1831-1836.	1.0	59
9	Leadless Pacemaker Implantation in Hemodialysis Patients. <i>JACC: Clinical Electrophysiology</i> , 2019, 5, 162-170.	1.3	54
10	Prognostic value of CHA ₂ DS ₂ -VASc score in patients with non-valvular atrial fibrillation™ and valvular heart disease: the Loire Valley Atrial Fibrillation Project. <i>European Heart Journal</i> , 2015, 36, 1822.2-1830.	1.0	53
11	Galectin-3 in Atrial Fibrillation: Mechanisms and Therapeutic Implications. <i>International Journal of Molecular Sciences</i> , 2018, 19, 976.	1.8	52
12	Serum Galectin-3 Levels Predict Recurrences after Ablation of Atrial Fibrillation. <i>Scientific Reports</i> , 2016, 6, 34357.	1.6	45
13	Long-term follow-up on high-rate cut-off programming for implantable cardioverter defibrillators in primary prevention patients with left ventricular systolic dysfunction. <i>Europace</i> , 2012, 14, 968-974.	0.7	41
14	Tachycardiomyopathy Secondary to Nonreentrant Atrioventricular Nodal Tachycardia: Recovery After Slow Pathway Ablation. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2007, 30, 925-928.	0.5	34
15	Oral anticoagulation, stroke and thromboembolism in patients with atrial fibrillation and valve bioprosthesis. <i>Thrombosis and Haemostasis</i> , 2016, 115, 1056-1063.	1.8	33
16	Development and Validation of a New Scoring System to Predict Survival in Patients With Myotonic Dystrophy Type 1. <i>JAMA Neurology</i> , 2018, 75, 573.	4.5	32
17	Changes in glomerular filtration rate and outcomes in patients with atrial fibrillation. <i>American Heart Journal</i> , 2018, 198, 39-45.	1.2	31
18	Pacemaker Implantation After Balloon- or Self-Expandable Transcatheter Aortic Valve Replacement in Patients With Aortic Stenosis. <i>Journal of the American Heart Association</i> , 2020, 9, e015896.	1.6	30

#	ARTICLE	IF	CITATIONS
19	Risk stratification of cardiovascular and heart failure hospitalizations using integrated device diagnostics in patients with a cardiac resynchronization therapy defibrillator. <i>Europace</i> , 2018, 20, e69-e77.	0.7	29
20	Very high rate programming in primary prevention patients with reduced ejection fraction implanted with a defibrillator: Results from a large multicenter controlled study. <i>Heart Rhythm</i> , 2017, 14, 211-217.	0.3	24
21	Incident Comorbidities, Aging and the Risk of Stroke in 608,108 Patients with Atrial Fibrillation: A Nationwide Analysis. <i>Journal of Clinical Medicine</i> , 2020, 9, 1234.	1.0	24
22	Pacemaker complications and costs: a nationwide economic study. <i>Journal of Medical Economics</i> , 2019, 22, 1171-1178.	1.0	22
23	Mortality After Atrioventricular Nodal Radiofrequency Catheter Ablation With Permanent Ventricular Pacing in Atrial Fibrillation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2016, 9, .	2.1	21
24	Galectin-3 level predicts response to ablation and outcomes in patients with persistent atrial fibrillation and systolic heart failure. <i>PLoS ONE</i> , 2018, 13, e0201517.	1.1	20
25	Position paper for management of elderly patients with pacemakers and implantable cardiac defibrillators: Groupe de Rythmologie et Stimulation Cardiaque de la Soci��t�� Fran��aise de Cardiologie and Soci��t�� Fran��aise de G��riatrie et G��rontologie. <i>Archives of Cardiovascular Diseases</i> , 2016, 109, 563-585.	0.7	19
26	Stroke and Thromboembolism in Patients With Atrial Fibrillation and Mitral Regurgitation. <i>Circulation: Arrhythmia and Electrophysiology</i> , 2019, 12, e006990.	2.1	17
27	Stroke, thromboembolism and bleeding in patients with atrial fibrillation according to the EHRA valvular heart disease classification. <i>International Journal of Cardiology</i> , 2018, 260, 93-98.	0.8	15
28	Galectin-3 in patients undergoing ablation of atrial fibrillation. <i>IJC Metabolic & Endocrine</i> , 2014, 5, 56-60.	0.5	11
29	Galectin-3 predicts response and outcomes after cardiac resynchronization therapy. <i>Journal of Translational Medicine</i> , 2018, 16, 299.	1.8	11
30	Outcomes associated with pacemaker implantation following transcatheter aortic valve replacement: A nationwide cohort study. <i>Heart Rhythm</i> , 2021, 18, 2027-2032.	0.3	9
31	Insufficiency of electrocardiogram alone in predicting infrahisian abnormalities in patients with type 1 myotonic dystrophy. <i>International Journal of Cardiology</i> , 2014, 172, 625-627.	0.8	8
32	The Defibrillation Conundrum: New Insights into the Mechanisms of Shock-Related Myocardial Injury Sustained from a Life-Saving Therapy. <i>International Journal of Molecular Sciences</i> , 2021, 22, 5003.	1.8	8
33	Benefits of an early management of palpitations. <i>Medicine (United States)</i> , 2018, 97, e11466.	0.4	7
34	Nonsustained Ventricular Tachycardia at the Time of Implantation Predicts Appropriate Therapies on Rapid Ventricular Arrhythmia in Primary Prevention Patients With Nonischemic Cardiomyopathy. <i>JACC: Clinical Electrophysiology</i> , 2017, 3, 1338-1339.	1.3	6
35	Outcomes in patients with acute myocardial infarction and history of illicit drug use: a French nationwide analysis. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2021, 10, 1027-1037.	0.4	6
36	Successful 'quadrangular' pacing in a non-responder patient to cardiac resynchronization therapy. <i>European Heart Journal</i> , 2011, 32, 2215-2215.	1.0	5

#	ARTICLE	IF	CITATIONS
37	Acute pathophysiological myocardial changes following intra-cardiac electrical shocks using a proteomic approach in a sheep model. <i>Scientific Reports</i> , 2020, 10, 20252.	1.6	5
38	Cardiovascular outcomes after cardiac resynchronization therapy in cardiac amyloidosis. <i>ESC Heart Failure</i> , 2022, 9, 740-750.	1.4	5
39	Major ST-segment elevation hiding acute severe pancreatitis. <i>American Journal of Emergency Medicine</i> , 2010, 28, 116.e1-116.e3.	0.7	4
40	Programming implantable cardioverter-defibrillators in primary prevention: Higher or later. <i>Archives of Cardiovascular Diseases</i> , 2014, 107, 308-318.	0.7	4
41	Severe recurrent vasovagal syncope and multidisciplinary rehabilitation: A prospective randomized pilot study. <i>International Journal of Cardiology</i> , 2015, 187, 658-659.	0.8	4
42	Leadless cardiac pacemaker implantation in patient with active tricuspid endocarditis. <i>Europace</i> , 2021, 23, 1794-1794.	0.7	4
43	Electrogram morphology discriminators in implantable cardioverter defibrillators: A comparative evaluation. <i>Journal of Cardiovascular Electrophysiology</i> , 2020, 31, 1493-1506.	0.8	3
44	Leadless pacemaker implant with concomitant atrioventricular node ablation: Experience with the Micra transcatheter pacemaker. <i>Journal of Cardiovascular Electrophysiology</i> , 2021, 32, 832-841.	0.8	3
45	Leadless pacemakers in critically ill patients requiring prolonged cardiac pacing: A multicenter international study. <i>Journal of Cardiovascular Electrophysiology</i> , 2021, 32, 2522-2527.	0.8	3
46	Leadless pacemakers: learning from experience. <i>Europace</i> , 2019, 21, 356-356.	0.7	2
47	Three-dimensional interlead distance predicts response and outcomes after cardiac resynchronization therapy. <i>Archives of Cardiovascular Diseases</i> , 2017, 110, 590-598.	0.7	1
48	Prognosis of Type 2 Myocardial Infarction Patients Implanted With a Prophylactic Defibrillator (from) <i>Tj ETQqO O O rgBT /Overlock 10 Tf</i>	0.7	1
49	To the Editorâ€”Fear does not avoid the danger!. <i>Heart Rhythm</i> , 2021, 18, 161.	0.3	1
50	Atrioventricular Nodal Reentrant Tachycardia Ablation Using Mini-Electrode Recordings. <i>Journal of Clinical Medicine</i> , 2022, 11, 282.	1.0	1
51	Physiological pacing with a DFâ€” single chamber defibrillator in a patient with permanent atrial fibrillation and heart block: A case report. <i>Journal of Cardiovascular Electrophysiology</i> , 2022, , .	0.8	1
52	Atrial flutter: Right, left, or both?. <i>Heart Rhythm</i> , 2012, 9, 844-845.	0.3	0
53	Pacemaker â€œDysfunctionâ€”Treated by Radiofrequency Ablation. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2013, 36, 772-774.	0.5	0
54	How to upgrade a leadless pacemaker to cardiac resynchronization therapy. <i>Journal of Cardiovascular Electrophysiology</i> , 2019, 30, 2578-2581.	0.8	0

#	ARTICLE	IF	CITATIONS
55	End-of-service management of leadless cardiac pacemakers: a case report. <i>Europace</i> , 2019, 21, 1245-1245.	0.7	0
56	Distal-to-proximal delay for ablation of premature ventricular contractions. <i>Journal of Cardiovascular Electrophysiology</i> , 2019, 30, 205-211.	0.8	0
57	The ICAD score for predicting prophylactic cardioverter-defibrillator implantation following acute myocardial infarction. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2021, 44, 973-979.	0.5	0